Search Results - "Bonifati, C"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study by Bonifati, C., De Felice, C., Lora, V., Morrone, A., Graceffa, D.

    Published in The Journal of dermatological treatment (02-10-2020)
    “…Background: Currently, there are no studies specifically aimed at investigating the effectiveness of etanercept biosimilar SB4 in psoriatic arthritis (PsA)…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis by Graceffa, D., Maiani, E., Sperduti, I., Ceralli, F., Bonifati, C.

    Published in Clinical and experimental dermatology (01-03-2015)
    “…Summary Background The data in the literature concerning the frequency of remission of inflammatory arthritis in patients with psoriatic arthritis (PsA) are…”
    Get full text
    Journal Article
  7. 7

    Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease by Strippoli, G F M, Bonifati, C, Craig, M, Navaneethan, S D, Craig, J C

    Published in Cochrane database of systematic reviews (18-10-2006)
    “…Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA) are considered to be equally effective for patients with…”
    Get more information
    Journal Article
  8. 8
  9. 9
  10. 10

    The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasis by Bonifati, C., Elia, F., Francesconi, F., Ceralli, F., Izzi, S., Solivetti, F.M., De Mutiis, C.

    “…Background  Most of the data currently available on early psoriatic arthritis (EPsA) derive from studies performed in rheumatological settings. However, in…”
    Get full text
    Journal Article
  11. 11

    hMena: altered expression in psoriatic skin by Cardinali, G., Kovacs, D., Mastrofrancesco, A., Cota, C., Donati, P., Cordiali-Fei, P., Francesconi, F., Bonifati, C.

    Published in Archives of Dermatological Research (01-12-2013)
    “…Psoriasis is a chronic inflammatory skin disease, characterized by an enhanced proliferation and a deregulated differentiation of keratinocytes. hMena is an…”
    Get full text
    Journal Article
  12. 12

    Simultaneous occurrence of linear scleroderma and homolateral segmental vitiligo by Bonifati, C, Impara, G, Morrone, A, Pietrangeli, A, Carducci, M

    “…Localized scleroderma and vitiligo only rarely have been reported to occur simultaneously. Here we report a case of a 21 year old man affected with both linear…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Clinical outcome measures of psoriasis by Bonifati, C, Berardesca, E

    Published in Reumatismo (01-01-2007)
    “…Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic…”
    Get full text
    Journal Article
  15. 15

    Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis by Barile, S., Medda, E., Nisticò, L., Bordignon, V., Cordiali-Fei, P., Carducci, M., Rainaldi, A., Marinelli, R., Bonifati, C.

    Published in Experimental dermatology (01-05-2006)
    “…:  We investigated the relationship between eight polymorphisms in the gene encoding for vascular endothelial growth factor (VEGF) (−1540C > A, −1512Ins18,…”
    Get full text
    Journal Article
  16. 16

    Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity by AMEGLIO, F, D'AURIA, L, BONIFATI, C, FERRARO, C, MASTROIANNI, A, GIACALONE, B

    Published in British journal of dermatology (1951) (01-04-1998)
    “…Few and contrasting data are available in the literature concerning the levels of various cytokines in blister fluid (BF) and in the serum of patients affected…”
    Get full text
    Journal Article Conference Proceeding
  17. 17
  18. 18

    Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy by Izzi, S, Francesconi, F, Visca, P, Altieri, A, De Mutiis, C, Trevisan, G, Bonifati, C

    Published in Dermatology online journal (15-05-2010)
    “…The occurrence of sarcoidosis during anti-TNF-alpha therapy has occasionally been published. We report the case of a psoriasis patient who developed pulmonary…”
    Get full text
    Journal Article
  19. 19

    Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma by Graceffa, Dario, Bonifati, C., De Mutiis, C., Elia, F., Maiani, E., Pace, Andrea, Solivetti, Francesco M.

    Published in Case reports in rheumatology (01-01-2012)
    “…Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination…”
    Get full text
    Journal Article
  20. 20